Conference Coverage

Baricitinib shows encouraging phase III results in RA


 

AT THE ACR ANNUAL MEETING

References

If baricitinib gains Food and Drug Administration approval for the treatment of RA, Dr. Taylor predicted that as experience is gained, it will be used “relatively early” in the course of treatment, but he acknowledged that cost will enter into the discussion.

Eli Lilly & Co. and Incyte Corporation sponsored the study. All investigators reported ties with Lilly, and some had ties with other companies marketing RA drugs.

Pages

Recommended Reading

Jury still out on cannabinoid therapy for rheumatic diseases
MDedge Rheumatology
VIDEO: Real-world proof that treat-to-target works in rheumatoid arthritis
MDedge Rheumatology
Study backs broader use of aspirin to prevent preeclampsia
MDedge Rheumatology
VIDEO: Obesity decreased chances of sustained RA remission
MDedge Rheumatology
VIDEO: Trial points to using non-TNF biologic when first anti-TNF drug fails
MDedge Rheumatology
VIDEO: How to handle pregnancy and breast feeding in rheumatoid arthritis
MDedge Rheumatology
ACR: Mortality gap narrows between RA patients and general population
MDedge Rheumatology
Shingles vaccine protection lasted about 5 years in autoimmune disease patients
MDedge Rheumatology
Gout hospitalizations, costs surpass those for rheumatoid arthritis
MDedge Rheumatology
Multibiomarker blood test could aid treatment decisions in RA
MDedge Rheumatology

Related Articles